6:24 PM
 | 
Jun 28, 2013
 |  BC Extra  |  Top Story

CHMP backs first biosimilar mAb

EMA's CHMP backed approval of the first biosimilar mAb on Friday -- a biosimilar from Celltrion Inc. (KOSDAQ:068270) and partner Hospira Inc. (NYSE:HSP) of autoimmune drug Remicade infliximab. Hospira plans to launch the biosimilar as Inflectra in Eastern and Central Europe by year end and...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >